ArticleEuropean journal of nuclear medicine and molecular imaging2026
Prospective head-to-head comparison of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03606837 (Exploratory, Single-institution Study, Comparing 68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Patients Diagnosed With Intermediate Risk Prostate Cancer Candidates for Radical Prostatectomy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory, Single-institution Study, Comparing 68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Patients Diagnosed With Intermediate Risk Prostate Cancer Candidates for Radical Prostatectomy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeIntermediate-risk (IR) prostatic adenocarcinoma is an heterogeneous subgroup of prostate cancer with discrepant progression and prognosis. These tumors can be subclassified based on the ISUP (International Society of Urology Pathology) score into favorable (ISUP 2) and unfavorable (ISUP 3) IR prostate cancer. Positron Emission Tomography / Computed Tomography (PET/CT) imaging targeting PSMA (Prostate Specific Membrane Antigen) is recommended for the assessment of high-risk prostate cancers. On the other hand, GRPR (Gastrin-Releasing Peptide Receptor) is over-expressed in low-risk prostate cancers (low ISUP score, low PSA and small tumor size). The aim of this study is to evaluate the relevance of PSMA- and GRPR-targeted PET/CT imaging for primary tumor stratification in newly diagnosed intermediate-risk patients.
methods22 patients with biopsy-confirmed intermediate-risk prostate cancer with no prior treatment and candidates for radical prostatectomy were imaged with [68Ga]Ga-PSMA-617 (a radiolabeled PSMA-inhibitor) and [68Ga]Ga-RM2 (a radiolabeled GRPR antagonist). Histology served as reference. Magnetic Resonance Imaging (MRI) was available in 18 patients.
results[68Ga]Ga-RM2 SUVmax was significantly higher than [68Ga]Ga-PSMA-617 SUVmax in ISUP ≤ 2 lesions (p = 0.027). [68Ga]Ga-PSMA-617 SUVmax was significantly higher in ISUP ≥ 3 lesions than ISUP ≤ 2 lesions (p = 0.001)
conclusionThese results suggest that the combined use of PSMA imaging and GRPR imaging is able to discriminate ISUP 2 from ISUP 3 prostate cancer and thus provides valuable information for treatment decision making. TRIAL REGISTRATION NUMBER: NCT03606837 (prospectively registered on 11/07/2019).
Indexed as
Identifiers
41656418What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.